No profile data available.
Aura Biosciences, Inc. (AURA) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 113 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$106.19 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $678.23 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Aura Biosciences reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$678.23 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Candel Therapeutics, Inc. (CADL), Verastem, Inc. (VSTM), Nuvectis Pharma, Inc. (NVCT), CytomX Therapeutics, Inc. (CTMX).